Radar · Life Sciences in New York City
Best Life Sciences Companies in New York City, United States
The 665 best Life Sciences companies in New York City, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Immunovant.
By Riya SenguptaFinancials
665companies tracked
$15.4Bdisclosed funding
4unicorns
375have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × NEW YORK CITY
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
379kcombined LinkedIn audience
32%of audience held by top 3
4companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in New York City
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Immunovant Provider of therapeutics solutions for treating autoimmune diseases 29Funding top 16%News top 45%Moat top 48%Tech bottom 48% All 7 signals ▾Fundingtop 16% Newstop 45% Moattop 48% Techbottom 48% Growthbottom 47% Globalbottom 41% Marketbottom 25% Funding: Raised $685M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) News: 7 BI events in 12 mo (of 46 tracked, 7 types) · -50% YoY rank vs industry peers · Fliar Intelligence Index 29/100 | $685M | 17 mo ago | 1 | — | Apple iCloud MailBootstrapAmazon Web Services+20 | — | — |
| 2 | Formation Bio 🦄 Provider of AI-powered drug discovery platform for various diseases | $608M | 24 mo ago | — | Benjamine Liu Co-Founder & CEO | SanityTurbopackApple iCloud Mail+12 | — | — |
| 3 | Immunic Developer of oral immunology therapies for treating chronic inflammatory and autoimmune diseases 35Funding top 19%Tech top 41%Moat top 48%Growth top 50% All 9 signals ▾Fundingtop 19% Techtop 41% Moattop 48% Growthtop 50% Talentbottom 49% Globalbottom 45% Newsbottom 40% Marketbottom 38% Fin. healthbottom 20% Funding: Raised $560M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) Tech: 34 technologies across 3/8 capability areas · Cloud: Cloudflare, Google Cloud rank vs industry peers · Fliar Intelligence Index 35/100 | $560M | 4 mo ago | 77 77 → 91 (+18%) | Daniel Vitt Chief Executive Officer | Froala EditorPHPHighcharts+18 | — | — |
| 4 | Delcath Speciality Pharmaceutical and medical device company focused on oncology 74Product top 14%Funding top 20%Fin. health top 31%Innovation top 34% All 10 signals ▾Producttop 14% Fundingtop 20% Fin. healthtop 31% Innovationtop 34% Techtop 37% Growthtop 39% Markettop 43% Moattop 47% Newstop 48% Globalbottom 44% Product: 5 distinct product lines · Company stage: Public Funding: Raised $307M across 19 rounds · 19 rounds over 24 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 74/100 | $307M | 17 mo ago | 52 | — | WordPressApple iCloud MailMicrosoft 365+26 | — | — |
| 5 | LEXEO Therapeutics Developer of gene therapy for the treatment of CLN2 Batten and Alzheimer's diseases 29Funding top 19%News top 43%Growth top 47%Tech bottom 49% All 9 signals ▾Fundingtop 19% Newstop 43% Growthtop 47% Techbottom 49% Talentbottom 40% Globalbottom 39% Marketbottom 31% Moatbottom 31% Fin. healthbottom 29% Funding: Raised $185M across 9 rounds · 9 rounds over 5 yrs (1.8/yr) News: 7 BI events in 12 mo (of 27 tracked, 4 types) · -36% YoY rank vs industry peers · Fliar Intelligence Index 29/100 | $185M | 7 mo ago | 58 58 → 97 (+67%) | Nolan Townsend CEO | DrupalPHPGoogle Maps+19 | — | 1 launch |
| 6 | TMRW Provider of an automated platform for patients and clinics to manage frozen eggs and embryos | $177M | 23 mo ago | 93 93 → 63 (-32%) | Jeffrey Port Founder | — | — | — |
| 7 | Precision Neuroscience Developed of brain-computer interface tool for medical treatment and drug development 50Funding top 18%Moat top 31%Talent top 38%Tech top 39% All 9 signals ▾Fundingtop 18% Moattop 31% Talenttop 38% Techtop 39% AItop 45% Growthbottom 40% Globalbottom 37% Marketbottom 34% Newsbottom 18% Funding: Raised $174M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 50/100 | $174M | 7 mo ago | 22 | Benjamin Rapoport Co-Founder & CSO | SanityTurbopackApple iCloud Mail+21 | — | 1 job opening · 2 launchs · 1 award |
| 8 | EvolutionaryScale Provider of an AI models for protein design | $142M | 23 mo ago | — | Thomas Hayes Co-Founder | WebflowGSAPAmazon Web Services+10 | — | — |
| 9 | LB Pharmaceuticals Developer of small molecule based therapeutics for schizophrenia 67Moat top 21%Growth top 23%Patents top 25%News top 27% All 10 signals ▾Moattop 21% Growthtop 23% Patentstop 25% Newstop 27% Fundingtop 30% Innovationtop 34% Talenttop 41% Marketbottom 44% Globalbottom 43% Partnersbottom 35% Moat: Editorial + unicorn rating 7/10 · IP moat: 437 patents Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 67/100 | $130M | 4 mo ago | — | Zachary Prensky Founder & CEO | — | 437 patents Small-molecule immunomodulators targeting CXCR4/CXCR2, BTK, complement, and IL-6 pathways | — |
| 10 | Volastra Developer of therapeutics for cancer treatment 40Funding top 24%Talent top 28%Moat top 39%Tech bottom 48% All 6 signals ▾Fundingtop 24% Talenttop 28% Moattop 39% Techbottom 48% Globalbottom 37% Marketbottom 31% Funding: Raised $87.2M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 40/100 | $87M | 9 mo ago | 21 21 → 41 (+95%) | Samuel Bakhoum Co-Founder | WordPressApple iCloud MailMicrosoft 365+24 | — | 1 job opening |
| 11 | Proxima Developer of a platform for programmable protein interaction-based drug discovery 42Funding top 24%Talent top 38%AI top 45%Tech bottom 45% All 6 signals ▾Fundingtop 24% Talenttop 38% AItop 45% Techbottom 45% Globalbottom 33% Marketbottom 31% Funding: Raised $86.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $86M | 5 mo ago | — | Luca Naef Co-Founder & CTO | Node.jsHeadless UITailwind CSS+9 | — | — |
| 12 | Leal Therapeutics Developer of therapeutics to treat neurological diseases 32Funding top 21%Moat top 42%Talent bottom 49%Market bottom 36% All 5 signals ▾Fundingtop 21% Moattop 42% Talentbottom 49% Marketbottom 36% Globalbottom 29% Funding: Raised $84.0M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 32/100 | $84M | 9 mo ago | 25 | Asa Abeliovich Founder & CEO | — | — | — |
| 13 | Rocket Pharma Developer of gene-modified cell therapies for the treatment of rare diseases 60Funding top 24%Tech top 32%Market top 42%News top 46% All 7 signals ▾Fundingtop 24% Techtop 32% Markettop 42% Newstop 46% Moattop 48% Growthtop 50% Globalbottom 32% Funding: Raised $83.2M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Tech: 54 technologies across 5/8 capability areas · Cloud: Akamai, Amazon Web Services rank vs industry peers · Fliar Intelligence Index 60/100 | $83M | 17 mo ago | 268 268 → 222 (-17%) | — | WordPressApple iCloud MailMySQL+34 | — | 1 internship |
| 14 | Gilgamesh Developer of drugs for neuropsychiatric conditions 62Growth top 15%Funding top 17%Talent top 23%News top 28% All 9 signals ▾Growthtop 15% Fundingtop 17% Talenttop 23% Newstop 28% Moattop 39% AItop 45% Techbottom 40% Globalbottom 39% Marketbottom 21% Growth: Fresh capital in last 24 mo Funding: Raised $83.1M across 13 rounds · 13 rounds over 6 yrs (2.2/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $83M | 2 mo ago | 2 | Jonathon Sporn Co-Founder & CEO | WebflowjQueryHSTS+8 | — | — |
| 15 | Cresilon Developer of hemostatic products for wound care 60Funding top 22%Growth top 32%Moat top 32%Product top 35% All 10 signals ▾Fundingtop 22% Growthtop 32% Moattop 32% Producttop 35% Techtop 37% Patentstop 42% Innovationtop 48% Marketbottom 46% Globalbottom 36% Newsbottom 18% Funding: Raised $81.7M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) Growth: Headcount 53 → 73 (+38%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $82M | 1 mo ago | 73 | — | WordPressApple iCloud MailMicrosoft 365+36 | 40 patents Hemostatic polymer adhesives and delivery devices for rapid surgical bleeding control | — |
| 16 | Intra-Cellular Therapies Developer of therapeutics for psychiatric and neurologic diseases 78Patents top 20%Moat top 23%Funding top 26%Market top 27% All 11 signals ▾Patentstop 20% Moattop 23% Fundingtop 26% Markettop 27% Fin. healthtop 27% Innovationtop 29% Producttop 36% Growthtop 40% Techbottom 46% Globalbottom 42% Newsbottom 23% Patents: 1,493 patents matched (strict assignee match) · 508 filings since 2022 vs 551 in 2017-21 Moat: Top 11% by revenue among 18 tracked Neurology companies · Editorial + unicorn rating 6/10 rank vs industry peers · Fliar Intelligence Index 78/100 | $81M | 13 mo ago | 610 610 → 639 (+5%) | — | WordPressMySQLPHP+17 | 1,493 patents Novel heterocyclic small‑molecule therapeutics, especially deuterated CNS drug candidates. | — |
| 17 | Nanit Provider of smart baby monitoring systems with sleep and breathing analysis 74Funding top 19%Tech top 20%Moat top 24%Talent top 28% All 10 signals ▾Fundingtop 19% Techtop 20% Moattop 24% Talenttop 28% Producttop 30% Markettop 36% Customerstop 37% Growthbottom 47% Globalbottom 43% Newsbottom 33% Funding: Raised $75.0M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) Tech: 73 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Web Services rank vs industry peers · Fliar Intelligence Index 74/100 | $75M | 6 mo ago | 111 | Andrew Berman Co-Founder | Cart FunctionalityShopifySentry+42 | — | 3 launchs · 1 award |
| 18 | Elysium Developer and manufactures of cellular health supplements 53Tech top 24%Funding top 28%Moat top 31%Growth top 35% All 11 signals ▾Techtop 24% Fundingtop 28% Moattop 31% Growthtop 35% Producttop 45% Marketbottom 49% Talentbottom 49% Globalbottom 39% Innovationbottom 31% Patentsbottom 29% Newsbottom 27% Tech: 72 technologies across 5/8 capability areas · Cloud: Amazon S3, Amazon Ses Funding: Raised $71.2M across 7 rounds · 7 rounds over 10 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $71M | 12 mo ago | — | Dan Alminana Founder & COO | Cart FunctionalityShopifyApple iCloud Mail+40 | 6 patents Patents concentrated in transport & manufacturing processes | — |
| 19 | ILiAD Biotechnologies Developer of immunity-inducing vaccine for the prevention and treatment of pertussis 24Funding top 25%Moat top 36%Patents top 38%Innovation top 42% All 9 signals ▾Fundingtop 25% Moattop 36% Patentstop 38% Innovationtop 42% Newsbottom 49% Talentbottom 49% Globalbottom 36% Marketbottom 24% Techbottom 22% Funding: Raised $51.2M across 9 rounds · 9 rounds over 11 yrs (0.8/yr) Moat: Editorial + unicorn rating 5/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 24/100 | $51M | 4 mo ago | 8 | Keith Rubin Founder & CEO | YouTubeApache HTTP ServerSlider Revolution+6 | 24 patents Patents concentrated in health & consumer products | 1 partnership |
| 20 | Manas AI Provider of a platform for drug discovery for the treatment of cancer and rare diseases 62Funding top 24%Growth top 35%Tech top 42%AI top 45% All 7 signals ▾Fundingtop 24% Growthtop 35% Techtop 42% AItop 45% Talentbottom 49% Globalbottom 48% Marketbottom 40% Funding: Raised $50.6M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 62/100 | $51M | 8 mo ago | — | Siddhartha Mukherjee Co-Founder & CEO | Webflow EcommerceWebflowcore-js+12 | — | — |
| 21 | Peerbridge Health Developer of ambulatory ECG system with AI-enabled cardiac diagnostics 42Innovation top 23%Funding top 27%Product top 30%Moat top 39% All 7 signals ▾Innovationtop 23% Fundingtop 27% Producttop 30% Moattop 39% Techtop 48% Globalbottom 37% Marketbottom 19% Innovation: 4 product lines · Deep-tech classification: Tech Hardware Funding: Raised $46.1M across 14 rounds · 14 rounds over 11 yrs (1.3/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $46M | 13 mo ago | 3 | — | HubSpot CMS Hubcore-jsOWL Carousel+15 | — | 1 launch · 1 expansion |
| 22 | Indaptus Developer of immunotherapies for oncology and infectious diseases 19Funding top 35%Moat top 39%Talent bottom 49%Growth bottom 42% All 7 signals ▾Fundingtop 35% Moattop 39% Talentbottom 49% Growthbottom 42% Globalbottom 30% Marketbottom 24% Newsbottom 23% Funding: Raised $37.9M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Moat: Editorial + unicorn rating 6/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 19/100 | $38M | 12 mo ago | 6 | Jeffrey Meckler Chief Executive Officer | — | — | — |
| 23 | ARMGO Pharma Developer of small molecule therapeutics to treat debilitating cardiac and vascular disorders | $36M | 15 mo ago | 9 | — | — | — | — |
| 24 | IN8Bio Provider of immune based therapies for the treatment of cancer 50Funding top 27%Patents top 32%Moat top 38%Innovation top 39% All 10 signals ▾Fundingtop 27% Patentstop 32% Moattop 38% Innovationtop 39% Techtop 41% Newstop 42% Growthtop 45% Talentbottom 41% Marketbottom 39% Globalbottom 36% Funding: Raised $35.0M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) Patents: 33 patents matched (strict assignee match) · 25 filings since 2022 vs 8 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $35M | 5 mo ago | 31 31 → 25 (-19%) | William Ho Founder & CEO | DrupalPHPZURB Foundation+22 | 33 patents Engineered gamma‑delta T‑cell CAR immunotherapies for cancer treatment | — |
| 25 | PreciseDx Provider of an AI-based medical image analysis software for healthcare professionals 48Talent top 23%AI top 30%Funding top 32%Moat top 48% All 8 signals ▾Talenttop 23% AItop 30% Fundingtop 32% Moattop 48% Growthbottom 42% Globalbottom 37% Marketbottom 32% Newsbottom 18% Talent: 5 named leaders on record · 5 C-suite/founder profiles curated AI: Classified as an AI company · Product described with: ai-based rank vs industry peers · Fliar Intelligence Index 48/100 | $32M | 12 mo ago | 12 | Michael Donovan Co-Founder | — | — | — |
| 26 | Atommap Provider of physics-based and ML-augmented computational drug discovery platform 65Funding top 28%Talent top 35%Global bottom 25% All 3 signals ▾Fundingtop 28% Talenttop 35% Globalbottom 25% Funding: Raised $31.1M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 3 named leaders on record rank vs industry peers · Fliar Intelligence Index 65/100 | $31M | 3 mo ago | — | Yujie Wu Co-Founder & CTO | — | — | — |
| 27 | Ordaos Provider of an AI accelerator for biomedical research and drug discovery | $21M | 16 mo ago | 24 | Ulo Palm Md Cofounder | — | — | — |
| 28 | MEND Provider of dietary supplements to manage body immunity power 42Funding top 33%Growth top 35%Talent top 38%Moat top 48% All 7 signals ▾Fundingtop 33% Growthtop 35% Talenttop 38% Moattop 48% Techtop 49% Globalbottom 37% Marketbottom 27% Funding: Raised $20.3M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 42/100 | $20M | 4 mo ago | 10 | Eziah Syed Co-Founder & Chief of Growth & Innovation | ShopifyApple iCloud MailGoogle Workspace+21 | — | 1 job opening · 1 launch · 1 partnership |
| 29 | Autonomous Therapeutics Developer of drugs for influenza & other infectious diseases treatment | $17M | 14 mo ago | 21 | Ariel Weinberger Co-Founder & CEO | Cart FunctionalitySquarespace CommerceSquarespace+10 | — | — |
| 30 | Dandelion Health Provider of AI-powered real-world data platform for clinical development 37Talent top 28%Funding top 34%Moat top 39%AI top 45% All 6 signals ▾Talenttop 28% Fundingtop 34% Moattop 39% AItop 45% Globalbottom 37% Marketbottom 24% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $15.9M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $16M | 1 mo ago | 7 | Elliott Green Co-Founder & CEO | — | — | 1 partnership |
| 31 | ProofPilot Platform for the development & execution of research studies 48Product top 26%Talent top 28%Innovation top 38%Moat top 39% All 9 signals ▾Producttop 26% Talenttop 28% Innovationtop 38% Moattop 39% Fundingtop 41% Techbottom 47% Marketbottom 38% Globalbottom 36% Newsbottom 17% Product: 3 distinct product lines · Company stage: Series D Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 48/100 | $16M | 9 mo ago | 19 | — | — | — | 1 launch |
| 32 | Voom Medical Devices Provider of fusion-free minimally invasive bunion surgery solutions | $15M | 14 mo ago | — | Neal Blitz Founder & CEO | SentryReactEmotion+12 | — | 4 launchs |
| 33 | Imprint Developer of forensic immunology research tools | $15M | 13 mo ago | — | Victor Greiff Co-Founder | Cart FunctionalitySquarespace CommerceSquarespace+10 | — | — |
| 34 | ProJenX Developer of targeted therapies to treat amyotrophic lateral sclerosis (ALS) | $15M | 15 mo ago | 4 | Stan Abel President and Chief Executive Officer | — | — | — |
| 35 | Coridea Medical device incubator creating innovative solutions for cardiology, pulmonary, and renal patients 7Funding top 38%Moat top 45%Global bottom 43%Patents bottom 30% All 6 signals ▾Fundingtop 38% Moattop 45% Globalbottom 43% Patentsbottom 30% Marketbottom 21% Innovationbottom 21% Funding: Raised $12.5M across 14 rounds · 14 rounds over 15 yrs (0.9/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 5 patents rank vs industry peers · Fliar Intelligence Index 7/100 | $12M | 9 mo ago | 9 | — | — | 5 patents Patents concentrated in health & consumer products | — |
| 36 | Bond Biosciences Therapeutics for ion-related diseases using non-absorbed oral treatments 10Funding top 36%Talent top 38%Global bottom 29%Market bottom 11% All 4 signals ▾Fundingtop 36% Talenttop 38% Globalbottom 29% Marketbottom 11% Funding: Raised $11.8M · 6 rounds over 6 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 10/100 | $12M | 2 mo ago | 4 | Cory Berkland Co-Founder & CEO | — | — | — |
| 37 | Hexem bio Developer of stem cell-based therapies for aging and disease prevention 29Talent top 28%Funding top 41%Global top 45%Tech bottom 43% All 5 signals ▾Talenttop 28% Fundingtop 41% Globaltop 45% Techbottom 43% Marketbottom 25% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $10.4M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $10M | 2 mo ago | — | Mo Ebrahimkhani Co-Founder | WebflowApple iCloud MailGoogle Workspace+14 | — | — |
| 38 | Eyenovia Developer of microdose therapies for treating myopia | $10M | 11 mo ago | 41 | — | WordPressApple iCloud MailMicrosoft 365+25 | 122 patents Micro‑dose ophthalmic fluid delivery devices for precise eye drug administration | — |
| 39 | Climatic Developer of a respiratory device designed to improve lung health 35Talent top 38%Funding top 39%Tech bottom 37%Global bottom 33% All 4 signals ▾Talenttop 38% Fundingtop 39% Techbottom 37% Globalbottom 33% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $10.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $10M | 4 mo ago | — | Margaret Wishingrad Co-Founder | ShopifySeal SubscriptionsOkendo+14 | — | 2 launchs · 1 award |
| 40 | IBS Developer of fingerprint drug testing and sweat drug monitoring solutions 42Innovation top 23%Product top 35%Funding top 42%News top 42% All 10 signals ▾Innovationtop 23% Producttop 35% Fundingtop 42% Newstop 42% Techtop 45% Talentbottom 49% Growthbottom 47% Fin. healthbottom 34% Marketbottom 33% Globalbottom 30% Innovation: 4 new-product events in 24 mo · Deep-tech classification: Tech Hardware Product: 0 product launch events in 12 mo, 4 the year before · Company stage: Public rank vs industry peers · Fliar Intelligence Index 42/100 | $10M | 5 mo ago | 26 | Harry Simeonidis President and CEO IBS Inc | WordPressMySQLPHP+28 | — | — |
| 41 | Reia Developer of non-surgical device for pelvic prolapse | $9M | 13 mo ago | 7 | Paul Hanissian Co-Founder | Cart FunctionalitySquarespace CommerceSquarespace+19 | 23 patents Gynecologic pessary devices and applicators for pelvic organ prolapse treatment | — |
| 42 | Oligomerix Developer of therapeutics for Alzheimer’s disease and related neurodegenerative diseases | $8M | 12 mo ago | 11 | Eliot Davidowitz Co-Founder | — | 55 patents Small-molecule inhibitors targeting tau oligomer formation for neurodegenerative therapeutics | — |
| 43 | Axon Therapies Developer of ablation device for heart failure treatment | $7M | 8 mo ago | 18 | Mark Gelfand Co-Founder | — | 63 patents Endovascular splanchnic nerve ablation devices for cardiovascular and metabolic therapy | — |
| 44 | Sequential Bio Provider of in-vivio microbiome testing platform for skin care 48Funding top 35%Growth top 35%Talent top 38%Moat top 44% All 7 signals ▾Fundingtop 35% Growthtop 35% Talenttop 38% Moattop 44% Techtop 45% Globaltop 50% Marketbottom 30% Funding: Raised $6.4M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $6M | 3 mo ago | — | Oliver Worsley Co-Founder & CEO | Wix eCommerceWixSentry+17 | — | — |
| 45 | Regenosine Provides regenerative based therapies for osteoarthritis | $5M | 10 mo ago | 3 | Siddhesh Angle CEO | — | — | — |
| 46 | Ancilia Developer of microbiome therapies for immunology and oncology indications 19Funding top 37%Patents top 41%Innovation bottom 49%Moat bottom 49% All 7 signals ▾Fundingtop 37% Patentstop 41% Innovationbottom 49% Moatbottom 49% Globalbottom 43% Marketbottom 20% Newsbottom 18% Funding: Raised $4.2M across 6 rounds · 6 rounds over 2 yrs (3.0/yr) Patents: 11 patents matched (strict assignee match) · 9 filings since 2022 vs 2 in 2017-21 rank vs industry peers · Fliar Intelligence Index 19/100 | $4M | 4 mo ago | 5 | — | — | 11 patents Blockchain security analytics and microbiome modulation therapeutics | — |
| 47 | Nionyx Bio Developer of gene therapy solutions designed for precision and safety | $4M | 8 mo ago | — | Leszek Lisowski Co-Founder | — | — | — |
| 48 | Akari Therapeutics Developer of therapeutics for autoimmune and inflammatory diseases by targeting the complement system. | $2M | 6 mo ago | 5 | Ray Prudo Chairman | WordPressMySQLPHP+16 | — | — |
| 49 | Reme-D.Inc Developer of diagnostic kits for both human and animal diseases 27Patents top 30%Global top 38%Innovation top 41%Funding top 44% All 7 signals ▾Patentstop 30% Globaltop 38% Innovationtop 41% Fundingtop 44% Talentbottom 49% Techbottom 30% Marketbottom 25% Patents: 42 patents matched (strict assignee match) · 10 filings since 2022 vs 6 in 2017-21 Global: Patents filed in 3 jurisdictions · Investors from 3 countries beyond United States rank vs industry peers · Fliar Intelligence Index 27/100 | $2M | 2 mo ago | — | Salma Tammam Founder & CEO | WordPressMySQLPHP+23 | 42 patents Hydraulic control valves and pistons for rotary steerable drilling tools | — |
| 50 | PAVmed Developer of medical devices and biomarkers to detect various diseases | $845K | 4 mo ago | 107 | — | WebflowjsDelivrGoogle Hosted Libraries+7 | 50 patents Minimally invasive catheter systems for fluid control and fibrous tissue division. | — |
Top 12 Life Sciences companies in New York City
#1
Public · New York City, New York · founded 2003 · 77 employees$559.7Mraised▾
Public · New York City, New York · founded 2003 · 77 employees
Developer of oral immunology therapies for treating chronic inflammatory and autoimmune diseases. The product pipeline of the company includes vidofludimus calcium (IMU-838), a selective immune modulator for multiple sclerosis, IMU-935, a selective inverse agonist targeted for psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome and IMU-856, for bowel barrier dysfunction.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 19%Tech
top 41%Moat
top 48%Growth
top 50%Talent
bottom 49%Global
bottom 45%Funding: Raised $560M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) · Last round Post IPO (Feb 2026)
Tech: 34 technologies across 3/8 capability areas · Cloud: Cloudflare, Google Cloud · Security: Cloudflare Bot Management, Hsts
Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 12k LinkedIn followers — 3.2% of this cohort's audience
Funding rounds
- Feb 2026Post IPO$400M
- Jan 2024Post IPO$80M
- Oct 2022Post IPO$60M
- Sep 2016Post IPO$19.7M
Founders & team
Investors
BVF Partners, Janus Henderson Investors, Soleus Capital, RTW Investments, Adage Capital Management, Avidity Partners
Tech stack
Apache Http ServerBricksCloudflareCloudflare Bot ManagementCookiebotCore-Js
#2
Series B · New York City, New York · founded 2010 · 73 employees$81.7Mraised▾
Series B · New York City, New York · founded 2010 · 73 employees
Developer of hemostatic products for wound care. The company offers VETIGEL Hemostatic Gel(a prescription hemostatic gel kit for animal use only. It can stop moderate to severe bleeds in animals), and TRAUMAGEL a hemostatic device for temporary use to control external traumatic bleeding not amenable to tourniquet application.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 22%Growth
top 32%Moat
top 32%Product
top 35%Tech
top 37%Patents
top 42%Funding: Raised $81.7M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) · Last round Series B (Apr 2026)
Growth: Headcount 53 → 73 (+38%) across vintages · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 7/10 · IP moat: 40 patents · 9 curated direct competitors tracked
Funding rounds
- Apr 2026Series B$5M
- Nov 2025Series B$6.7M
- Apr 2024Series B$25M
- Aug 2023Series A$17.2M
Investors
Paulson Investment, Valued ventures, Hammerstone Capital, PKJ Ventures, IMEX VP Investment Group, Design Technologies
Tech stack
Apple Icloud MailAstraCdnjsCloudflareCloudflare Bot ManagementCookieyes
#3
Series B · New York City, New York · founded 2019 · 2 employees$83.1Mraised▾
Series B · New York City, New York · founded 2019 · 2 employees
Developer of drugs for neuropsychiatric conditions. The company has an AI-powered discovery and translational platform to develop novel psychotropic drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Products include GM-1020 and GM-2505 an oral NMDAR Antagonist.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Growth
top 15%Funding
top 17%Talent
top 23%News
top 28%Moat
top 39%AI
top 45%Growth: Fresh capital in last 24 mo
Funding: Raised $83.1M across 13 rounds · 13 rounds over 6 yrs (2.2/yr) · Last round Series B (Mar 2026)
Talent: 5 named leaders on record · 5 C-suite/founder profiles curated
Audience (LinkedIn): 11k LinkedIn followers — 3.0% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: CMC - Drug Substance professional
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. AbbVie) announced in 12 mo
Funding rounds
- Mar 2026Series B$2.2M
- Mar 2026Series B$60M
- Jan 2026Series B$6.1M
- May 2025Grant (prize money)$5.4M
Founders & team
Investors
Prime Movers Lab, Noetic Psychedelic Fund, Gron Ventures, Route 66 Ventures, JLS Fund, Palo Santo
Tech stack
CloudflareGoogle AnalyticsGoogle Font ApiGoogle Hosted LibrariesHstsHttp/3
#4
Public · New York City, New York · founded 2015$130.1Mraised▾
Public · New York City, New York · founded 2015
Developer of small molecule based therapeutics for schizophrenia. The company's lead product candidate LB-102, also known as N-methyl amisulpride, is very similar to the marketed antipsychotic amisulpride and differs by only one methyl group (CH3). The drug acts as an antagonist to dopamine (D2, D3), and 5-HT7 receptors and exerts the antipsychotic effect.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Moat
top 21%Growth
top 23%Patents
top 25%News
top 27%Funding
top 30%Innovation
top 34%Moat: Editorial + unicorn rating 7/10 · IP moat: 437 patents
Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo
Patents: 437 patents matched (strict assignee match) · 172 filings since 2022 vs 251 in 2017-21 · Latest publication 2026
Funding rounds
- Feb 2026Post IPO$100M
- Aug 2023Series C$110.7M
- Aug 2020Series B$10M
- Mar 2019Series A$1.6M
Founders & team
Investors
Tarnagulla Ventures
#5
Public · New York City, New York · founded 2018 · 58 employees$185Mraised▾
Public · New York City, New York · founded 2018 · 58 employees
Developer of gene therapy for the treatment of CLN2 Batten and Alzheimer's diseases. It has developed a lead candidate LX1001 APOE4 inhibitor that helps in treating Alzheimer’s andother neurological disorders. Its drug candidate LX2006 cardiomyopathy helps in the treatment of Friedreich’s Ataxia & other genetic disorders. It also provides LX1004 CLN2 drug that plays an important role in treating Batten disease.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 19%News
top 43%Growth
top 47%Tech
bottom 49%Talent
bottom 40%Global
bottom 39%Funding: Raised $185M across 9 rounds · 9 rounds over 5 yrs (1.8/yr) · Last round Post IPO (Oct 2025)
News: 7 BI events in 12 mo (of 27 tracked, 4 types) · -36% YoY · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 18k LinkedIn followers — 4.6% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Oct 2025Post IPO$10M
- May 2025Post IPO$80M
- Mar 2024Post IPO$95M
- Aug 2023Series B—
Founders & team
Investors
Sarepta, Longitude Capital, Omega Funds, PBM Capital, Lundbeck Foundation, Janus Henderson Investors
Tech stack
Apache Http ServerDreamhostGoogle AnalyticsGoogle MapsGoogle Tag ManagerJquery
#6
Series C · New York City, New York · founded 2021 · 22 employees$173.8Mraised▾
Series C · New York City, New York · founded 2021 · 22 employees
Developed of brain-computer interface tool for medical treatment and drug development. The company has developed a next-generation brain computing technology that has the ability to process medicine and computing. The brain implants have features for AI-based computing, device integration, and assessment of neurological illness for medicine development.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 18%Moat
top 31%Talent
top 38%Tech
top 39%AI
top 45%Growth
bottom 40%Funding: Raised $174M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series C (Nov 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 38k LinkedIn followers — 10.1% of this cohort's audience · 77 engagements/post (2.2× cohort median)
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Field Clinical Specialist, VP, Market Access
Activity (LinkedIn): 2 product launches · 1 awards announced in 12 mo
Funding rounds
- Nov 2025Series C—
- Jan 2025Series C—
- Oct 2024Series C$102M
- Mar 2024Series B$27.5M
Founders & team
Investors
Steadview, B Capital, General Equity Holdings, Duquesne Family Office, Forepont Capital Partners, Mubadala
Tech stack
Apple Icloud MailBase UiCloudflareCloudflare Bot ManagementCookieyesDocusign
#7
Series B · New York City, New York · founded 2012 · 8 employees$51.2Mraised▾
Series B · New York City, New York · founded 2012 · 8 employees
Developer of immunity-inducing vaccine for the prevention and treatment of pertussis. Its lead candidate BPZE1, a live attenuated Bordetella pertussis (BP) vaccine claims to induce sterilizing mucosal immunity and long-lasting protection against pertussis disease. The candidate is nasally administered BPZE to induce both mucosal and systemic potent immune responses.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 25%Moat
top 36%Patents
top 38%Innovation
top 42%News
bottom 49%Talent
bottom 49%Funding: Raised $51.2M across 9 rounds · 9 rounds over 11 yrs (0.8/yr) · Last round Series B (Feb 2026)
Moat: Editorial + unicorn rating 5/10 · IP moat: 24 patents · Soonicorn
Patents: 24 patents matched (strict assignee match) · 18 filings since 2022 vs 1 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. hVIVO) announced in 12 mo
Funding rounds
- Feb 2026Series B$115M
- Dec 2023Series A—
- Sep 2022Series A$42.8M
- May 2022Grant (prize money)$972.1K
Founders & team
Investors
Livent, Knottpartners, NIH, HHS, RA Capital Management, Janus Henderson Investors
#8
Seed · New York City, New York · founded 2019$86.3Mraised▾
Seed · New York City, New York · founded 2019
Developer of a platform for programmable protein interaction-based drug discovery. The company offers technologies to discover proximity modulators, including inducers, modulators, and blockers. It focuses on advancing artificial intelligence drug discovery through data generation.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 24%Talent
top 38%AI
top 45%Tech
bottom 45%Global
bottom 33%Market
bottom 31%Funding: Raised $86.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Jan 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
AI: Product described with: artificial intelligence
Audience (LinkedIn): 12k LinkedIn followers — 3.1% of this cohort's audience
Funding rounds
- Jan 2026Seed$86.3M
Founders & team
Investors
DCVC, NVentures, Braidwell, Roivant Sciences, AIX Ventures, Yosemite
Tech stack
Google WorkspaceHeadless UiHstsNext.JsNext.Js App RouterNode.Js
#9
Series D · New York City, New York · founded 2014 · 111 employees$75Mraised▾
Series D · New York City, New York · founded 2014 · 111 employees
Provider of smart baby monitoring systems with sleep and breathing analysis. The systems offer real-time safety notifications, video history, and personalized sleep coaching. Features include breathing motion monitoring without sensors and advanced sleep insights. The company provides a range of compatible accessories, including breathing wear and display screens. It also offers membership plans for expanded data and video history.
Fliar Intelligence Index™ 74how this company ranks against its industry peers
Funding
top 19%Tech
top 20%Moat
top 24%Talent
top 28%Product
top 30%Market
top 36%Funding: Raised $75.0M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) · Last round Series D (Dec 2025)
Tech: 73 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Web Services · Devops: Envoy, Varnish
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 2 curated direct competitors tracked
Audience (LinkedIn): 14k LinkedIn followers — 3.8% of this cohort's audience
Activity (LinkedIn): 3 product launches · 1 awards announced in 12 mo
Funding rounds
- Dec 2025Series D$50M
- Feb 2021Series C$25M
- May 2020Series C$21M
- May 2018Series B$14M
Founders & team
Investors
JVP, Upfront Ventures, RRE Ventures, Rho Capital Partners, Vulcan, Google Ventures
Tech stack
Ab TastyAmazon CloudfrontAmazon PayAmazon Web ServicesApple PayAttentive
#10
Series A · New York City, New York · founded 2020 · 7 employees$15.9Mraised▾
Series A · New York City, New York · founded 2020 · 7 employees
Provider of AI-powered real-world data platform for clinical development. It combines proprietary AI tools with extensive real-world patient data to accelerate clinical development and commercialization. The platform offers solutions across the product lifecycle, from early clinical research to post-approval market access. This includes tools to identify therapeutic targets, optimize patient pools for trials, generate regulatory-grade evidence, and quantify clinical and economic impact. The platform also provides AI algorithm training and validation services using diverse, multi-site datasets.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Talent
top 28%Funding
top 34%Moat
top 39%AI
top 45%Global
bottom 37%Market
bottom 24%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $15.9M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Series A (May 2026)
Moat: Editorial + unicorn rating 7/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 7k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. InVision Medical Technology) announced in 12 mo
Funding rounds
- May 2026Series A$14M
- Dec 2023Seed$15.9M
Founders & team
Investors
Primary Venture Partner, Sharp HealthCare, Moxxie Ventures, Phoenix Venture Partners, Floating Point, Healthier Capital
#11
Series C · New York City, New York · founded 2023$31.1Mraised▾
Series C · New York City, New York · founded 2023
Provider of physics-based and ML-augmented computational drug discovery platform. It offers Silicon Therapeutics and Roivant Discovery to deliver STING agonist, potent inhibitors against oncology target, and active molecules for therapeutic degradation of target proteins.
Fliar Intelligence Index™ 65how this company ranks against its industry peers
Funding
top 28%Talent
top 35%Global
bottom 25%Funding: Raised $31.1M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series C (Mar 2026)
Talent: 3 named leaders on record
Global: Single-market focus (United States)
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Mar 2026Series C$31.1M
Founders & team
#12
Series A · New York City, New York · founded 2014 · 10 employees$20.3Mraised▾
Series A · New York City, New York · founded 2014 · 10 employees
Provider of dietary supplements to manage body immunity power. The company has developed repair & recovery supplements for injury or surgery recovery that contains clinically studied proteins, amino acids, vitamins, minerals, and other nutrients to optimize healing. They claim that products are natural, gluten-free, non-GMO, and others.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 33%Growth
top 35%Talent
top 38%Moat
top 48%Tech
top 49%Global
bottom 37%Funding: Raised $20.3M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) · Last round Series A (Feb 2026)
Growth: Fresh capital in last 24 mo
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 6k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Nurse Practitioner, Medicals Assistant
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. ALLO Performance PLLC) announced in 12 mo
Funding rounds
- Feb 2026Series A$9.9M
- Jun 2025Series A$3.9M
- Jun 2025Conventional Debt—
- Apr 2023Series A$16.5M
Founders & team
Investors
Colorcon, GenHenn Capital, KEEN Growth Capital, Tech Council Ventures, iSelect Fund, Cerity Partners Ventures
Tech stack
Apple Icloud MailApple PayBootstrapCdnjsCloudflareDropbox
Funding & investor landscape
$15.4Btotal disclosed funding
367companies funded
1,139disclosed rounds
5rounds last 90 days
Most active investors
Y Combinator10 rounds
Notable founders
Daniel Vitt
Chief Executive Officer · Immunic
Jonathon Sporn
Co-Founder & CEO · Gilgamesh
Andrew Kruegel
Co-Founder · Gilgamesh
Zachary Prensky
Founder & CEO · LB Pharmaceuticals
Nolan Townsend
CEO · LEXEO Therapeutics
Benjamin Rapoport
Co-Founder & CSO · Precision Neuroscience
Michael Mager
Co-Founder and Chief Executive Officer · Precision Neuroscience
Keith Rubin
Founder & CEO · ILiAD Biotechnologies
Luca Naef
Co-Founder & CTO · Proxima
Zachary Carpenter
Co-Founder & CEO · Proxima
Andrew Berman
Co-Founder · Nanit
Tor Ivry
Founder & Cto · Nanit
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 42% across 2008–2026.
top research entities
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
leading researchers
Stylianos Chatzimanolis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Giannis Bolanakis · Ashley R Tetens · Tyler Findlay · Jordyn Craig-Schwartz
▲
Breakthroughs2,038 · 33%
▼ 41%→30% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Gene-focused breakthrough research is surging — papers rose from 33 to 164 across US biotech institutions.
rising sub-themes (early→recent)
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
Newly emergingIdentification (biology) 0→18 · Function (biology) 0→18 · Reporter gene 0→16
Landmark U1 snRNP regulates cancer cell migration and invasion in vitro · 7,224 cites
◆
Advancements2,118 · 34%
▲ 29%→35% share
▲1.2× share momentum0 median citations80% since 2021mostly empirical
Cell culture and gene expression advancements are intensifying simultaneously — both jumped from ~3 to 62 papers.
rising sub-themes (early→recent)
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
Newly emergingIdentification (biology) 0→27 · Probiotic 0→24 · Cultivar 0→23
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns1,006 · 16%
▼ 17%→15% share
▼0.9× share momentum0 median citations73% since 2021mostly empirical
Antibiotic resistance concern research is rising sharply — US biotech papers tripled from 15 to 45.
rising sub-themes (early→recent)
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Newly emergingQuality (philosophy) 0→27 · Animal health 0→14 · Integrated pest management 0→13
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · United States
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston351 · +0.52
New York319 · +0.47
SF Bay Area235 · +0.57
Philadelphia115 · +0.60
San Diego101 · +0.59
Seattle95 · +0.46
Chicago95 · +0.57
Los Angeles93 · +0.61
Pittsburgh65 · +0.54
Ann Arbor65 · +0.58
PATENT SIGNAL · United States
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
457,918 filings8,000 assigneespeak 51616/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Genentech18113
- UNIV California17975
- Regeneron Pharma16083
- Amgen10515
- Monsanto Technology9755
- UNIV Pennsylvania8528
- Harvard College7464
- UNIV Texas7384
Common questions
How many Life Sciences companies are there in New York City, United States?
Radar tracks 665 indexable Life Sciences companies headquartered in New York City, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in New York City, United States?
The Life Sciences companies in New York City, United States on this list have raised a combined $15.4B in disclosed equity funding across 367 funded companies.
Which is the highest-funded Life Sciences company in New York City, United States?
Immunovant is the highest-funded Life Sciences company in New York City, United States, with $685M in disclosed equity funding.
How many Life Sciences companies in New York City, United States are funded?
367 of the 665 Life Sciences companies in New York City, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in New York City, United States?
4 Life Sciences companies in New York City, United States on this list are valued at $1B or more.
Who are the top investors in New York City, United States Life Sciences companies?
The most active investors in New York City, United States Life Sciences companies on this list include HHS, Design Technologies, Alexandria, NIH, JLABS.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.